$DFLI
Dragonfly Energy Holdings Corp. Stock $dfli

$dfli Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223041072 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue		$15.89M	$26.12M
YoY Change		-39.16%
Cost Of Revenue		$11.32M	$19.08M
YoY Change		-40.68%
Gross Profit		$4.572M	$7.038M
YoY Change		-35.04%
Gross Profit Margin		28.77%	26.95%
Selling, General & Admin		$9.088M	$9.653M
YoY Change		-5.85%
% of Gross Profit		198.78%	137.16%
Research & Development		$1.385M	$753.0K
YoY Change		83.93%
% of Gross Profit		30.29%	10.7%
Depreciation & Amortization		$316.0K	$259.0K
YoY Change		22.01%
% of Gross Profit		6.91%	3.68%
Operating Expenses		$10.47M	$10.41M
YoY Change		0.64%	8849.86%
Operating Profit		-$5.901M	-$1.049M
YoY Change		462.42%	802.41%
Interest Expense		$3.977M	-$1.207M
YoY Change		-429.49%
% of Operating Profit
Other Income/Expense, Net		-$4.122M	-$1.166M
YoY Change		253.52%	-141.54%
Pretax Income		-$10.02M	-$1.880M
YoY Change		433.06%	-169.88%
Income Tax			$39.34K
% Of Pretax Income
Net Earnings		-$10.02M	-$1.920M
YoY Change		422.14%	-171.35%
Net Earnings / Revenue		-63.08%	-7.35%
Basic Earnings Per Share		-$0.17	-$0.19
Diluted Earnings Per Share		-$0.17	-$0.19
COMMON SHARES
Basic Shares Outstanding	59.55M shares	58.78M shares	15.81M
Diluted Shares Outstanding		58.74M shares	10.31M

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$13.24M	$10.52M
YoY Change		25.84%	1085.4%
Cash & Equivalents	$12.71M	$13.24M	$316.0K
Short-Term Investments
Other Short-Term Assets	$118.0K	$118.0K	$12.52M
YoY Change	-55.81%	-99.06%	3315.9%
Inventory	$38.78M	$41.91M	$39.49M
Prepaid Expenses
Receivables	$1.639M	$4.336M	$3.820M
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$55.92M	$63.02M	$487.0K
YoY Change	-23.91%	12839.56%	-61.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$15.97M	$15.88M	$14.69M
YoY Change	48.41%	8.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$32.00M
YoY Change			-75.08%
Other Assets			$1.254M
YoY Change
Total Long-Term Assets	$19.28M	$19.49M	$32.00M
YoY Change	26.26%	-39.08%	-75.08%
TOTAL ASSETS
Total Short-Term Assets	$55.92M	$63.02M	$487.0K
Total Long-Term Assets	$19.28M	$19.49M	$32.00M
Total Assets	$75.20M	$82.51M	$32.48M
YoY Change	-15.27%	154.02%	-74.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.26M	$9.889M	$990.6K
YoY Change	-23.87%	898.3%
Accrued Expenses		$12.05M	$32.76K
YoY Change		36689.89%	3175.9%
Deferred Revenue	$201.0K	$217.0K
YoY Change	-15.55%
Short-Term Debt		$0.00	$0.00
YoY Change
Long-Term Debt Due	$19.68M	$18.70M	$16.53M
YoY Change	2.29%	13.13%
Total Short-Term Liabilities	$40.38M	$41.02M	$1.613M
YoY Change	-0.47%	2443.71%	6341.98%
LONG-TERM LIABILITIES
Long-Term Debt			$24.18M
YoY Change
Other Long-Term Liabilities		$17.16M	$3.821M
YoY Change		348.99%	158.02%
Total Long-Term Liabilities	$6.915M	$17.16M	$28.00M
YoY Change	-81.24%	-38.74%	1790.92%
TOTAL LIABILITIES
Total Short-Term Liabilities	$40.38M	$41.02M	$1.613M
Total Long-Term Liabilities	$6.915M	$17.16M	$28.00M
Total Liabilities	$47.29M	$58.18M	$3.603M
YoY Change	-38.92%	1514.86%	139.23%
SHAREHOLDERS EQUITY
Retained Earnings	-$41.54M	-$43.96M	-$2.827M
YoY Change	53.09%	1455.37%	1051.59%
Common Stock	$6.000K	$6.000K	$317.00
YoY Change	50.0%	1792.74%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$27.91M	$24.34M	-$2.826M
YoY Change
Total Liabilities & Shareholders Equity	$75.20M	$82.51M	$32.48M
YoY Change	-15.27%	154.02%	-74.95%

Cashflow Statement

Concept	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$10.02M	-$1.920M
YoY Change	422.14%	-171.35%
Depreciation, Depletion And Amortization	$316.0K	$259.0K
YoY Change	22.01%
Cash From Operating Activities	-$11.09M	-$4.799M
YoY Change	131.05%	945.94%
INVESTING ACTIVITIES
Capital Expenditures	$3.936M	$1.246M
YoY Change	215.89%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$3.936M	-$1.246M
YoY Change	215.89%	-99.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-4.693M	15.51M
YoY Change	-130.26%	-88.05%
NET CHANGE
Cash From Operating Activities	-11.09M	-4.799M
Cash From Investing Activities	-3.936M	-1.246M
Cash From Financing Activities	-4.693M	15.51M
Net Change In Cash	-19.72M	9.462M
YoY Change	-308.38%	987.24%
FREE CASH FLOW
Cash From Operating Activities	-$11.09M	-$4.799M
Capital Expenditures	$3.936M	$1.246M
Free Cash Flow	-$15.02M	-$6.045M
YoY Change	148.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001847986
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q2	DFLI	Stock Issued During Period Value Shares Issued For Vested Restricted Stock Units StockIssuedDuringPeriodValueSharesIssuedForVestedRestrictedStockUnits		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
	us-gaap	Paid In Kind Interest PaidInKindInterest		usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	DFLI	Proceeds From Public Offering Atm Net ProceedsFromPublicOfferingAtmNet		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
	DFLI	Repayments Of Notes Payable One RepaymentsOfNotesPayableOne		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	DFLI	Proceeds From Exercise Of Investor Warrants ProceedsFromExerciseOfInvestorWarrants		usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid		usd
	DFLI	Recognition Of Warrant Liability RecognitionOfWarrantLiability		usd
	DFLI	Noncash Impact Of Cash Exercise Of Liability Classified Warrants NoncashImpactOfCashExerciseOfLiabilityClassifiedWarrants		usd
	DFLI	Cashless Exercise Of Liability Classified Warrants CashlessExerciseOfLiabilityClassifiedWarrants		usd
CY2023Q3	us-gaap	Property Plant And Equipment Useful Life Description Of Term Extensible Enumeration PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration	http://fasb.org/us-gaap/2023#LeaseholdImprovementsMember
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear		usd
CY2023Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding		shares
CY2022Q3	DFLI	Earnout Shares EarnoutShares		shares
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
	DFLI	Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodIntrinsicValue		usd
	DFLI	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodTotalIntrinsicValue		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40730
	dei	Entity Registrant Name EntityRegistrantName	DRAGONFLY ENERGY HOLDINGS CORP.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1873463
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1190 Trademark Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	#108
	dei	Entity Address City Or Town EntityAddressCityOrTown	Reno
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NV
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	89521
	dei	City Area Code CityAreaCode	(775)
	dei	Local Phone Number LocalPhoneNumber	622-3448
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	59550812	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13235000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17781000	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4336000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1444000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	41907000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	49846000	usd
CY2023Q3	DFLI	Prepaid Expense Other Than Inventory Current PrepaidExpenseOtherThanInventoryCurrent	823000	usd
CY2022Q4	DFLI	Prepaid Expense Other Than Inventory Current PrepaidExpenseOtherThanInventoryCurrent	1624000	usd
CY2023Q3	us-gaap	Supplies Supplies	2074000	usd
CY2022Q4	us-gaap	Supplies Supplies	2002000	usd
CY2023Q3	us-gaap	Prepaid Taxes PrepaidTaxes	529000	usd
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	525000	usd
CY2023Q3	us-gaap	Other Assets Current OtherAssetsCurrent	118000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	267000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	63022000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	73489000	usd
CY2023Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	16337000	usd
CY2022Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	10214000	usd
CY2023Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	275000	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	275000	usd
CY2023Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1727000	usd
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1709000	usd
CY2023Q3	DFLI	Vehicle Gross VehicleGross	33000	usd
CY2022Q4	DFLI	Vehicle Gross VehicleGross	195000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	18372000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12393000	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2496000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1633000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15876000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10760000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3615000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4513000	usd
CY2023Q3	us-gaap	Assets Assets	82513000	usd
CY2022Q4	us-gaap	Assets Assets	88762000	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	9889000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13475000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10788000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6247000	usd
CY2023Q3	us-gaap	Deposit Liability Current DepositLiabilityCurrent	217000	usd
CY2022Q4	us-gaap	Deposit Liability Current DepositLiabilityCurrent	238000	usd
CY2023Q3	DFLI	Uncertain Tax Position Liability UncertainTaxPositionLiability	128000	usd
CY2022Q4	DFLI	Uncertain Tax Position Liability UncertainTaxPositionLiability	128000	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	18700000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	19242000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1264000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1188000	usd
CY2023Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	36000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	10000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	41022000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	40528000	usd
CY2023Q3	DFLI	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	14165000	usd
CY2022Q4	DFLI	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	32831000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	351000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	492000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2565000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3541000	usd
CY2023Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	75000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	38000	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	17156000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	36902000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	58178000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	77430000	usd
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58880712	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58880712	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43272728	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43272728	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	68293000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	38461000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-43964000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-27133000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	24335000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11332000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	82513000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	88762000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15889000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26117000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	53954000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	66042000	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	11317000	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	19079000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	40541000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	46481000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	4572000	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	7038000	usd
	us-gaap	Gross Profit GrossProfit	13413000	usd
	us-gaap	Gross Profit GrossProfit	19561000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1385000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	753000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3332000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1951000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6005000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6336000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23114000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13778000	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3083000	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3358000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	11075000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	9331000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	10473000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	10447000	usd
	us-gaap	Operating Expenses OperatingExpenses	37521000	usd
	us-gaap	Operating Expenses OperatingExpenses	25060000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5901000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3409000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-24108000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5499000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	3977000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	1166000	usd
	us-gaap	Interest Expense InterestExpense	11905000	usd
	us-gaap	Interest Expense InterestExpense	3657000	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	145000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-19182000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4122000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1166000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7277000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3657000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10023000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4575000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16831000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9156000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-886000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1700000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-10023000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3689000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16831000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7456000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58736013	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38129422	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50166320	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37098990	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58736013	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38129422	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50166320	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37098990	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	14061000	usd
CY2022Q1	DFLI	Stock Issued During Period Value Retroactive Application Of Recapitalizations StockIssuedDuringPeriodValueRetroactiveApplicationOfRecapitalizations	2000000	usd
CY2022Q1	DFLI	Stockholders Equity Adjusted Balance StockholdersEquityAdjustedBalance	16061000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2298000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	288000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	113000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	14164000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1469000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	431000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	89000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	13215000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3689000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	436000	usd
CY2022Q3	DFLI	Stock Issued During Period Value Stock Purchase Agreement StockIssuedDuringPeriodValueStockPurchaseAgreement	15000000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	505000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	25467000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11332000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	4892000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	597000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	93000	usd
CY2023Q1	DFLI	Stock Issued During Period Value Exercise Of Public Warrants StockIssuedDuringPeriodValueExerciseOfPublicWarrants	747000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	10167000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4487000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	32315000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-11700000	usd
CY2023Q2	DFLI	Stock Issued During Period Value Common Stock Issued In Public Offering Net Of Costs StockIssuedDuringPeriodValueCommonStockIssuedInPublicOfferingNetOfCosts	7878000	usd
CY2023Q2	DFLI	Stock Issued During Period Value Common Stock Issued In Public Offering Atm Net Of Costs StockIssuedDuringPeriodValueCommonStockIssuedInPublicOfferingATMNetOfCosts	74000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	230000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	2462000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	954000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	32213000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	32213000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-10023000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-10023000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	36000	usd
CY2023Q3	DFLI	Stock Issued During Period Value Cash Exercise Of Liability Classified Warrants StockIssuedDuringPeriodValueCashExerciseOfLiabilityClassifiedWarrants	1163000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	946000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	24335000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	24335000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16831000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7456000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6387000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1155000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	995000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1783000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-19182000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1707000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	3738000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	147000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	909000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	648000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-116000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-62000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3039000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3037000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-7939000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	12360000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-801000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1259000	usd
	DFLI	Increase Decrease In Prepaid Inventory IncreaseDecreaseInPrepaidInventory	72000	usd
	DFLI	Increase Decrease In Prepaid Inventory IncreaseDecreaseInPrepaidInventory	-3732000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-149000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	2114000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-898000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-831000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-4000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-927000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	343000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3915000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-21000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-147000	usd
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	104000	usd
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-17255000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16727000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24711000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6507000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6065000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6507000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6065000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	21640000	usd
	DFLI	Proceeds From Public Offering Atm Net ProceedsFromPublicOfferingAtmNet	671000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1000000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1000000	usd
	DFLI	Repayments Of Notes Payable One RepaymentsOfNotesPayableOne	5275000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	747000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	359000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	707000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	15000000	usd
	DFLI	Proceeds From Exercise Of Investor Warrants ProceedsFromExerciseOfInvestorWarrants	546000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18688000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15707000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4546000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-15069000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17781000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28630000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13235000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13561000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	237000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	981000	usd
	us-gaap	Interest Paid Net InterestPaidNet	6740000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1873000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	53000	usd
	DFLI	Recognition Of Warrant Liability RecognitionOfWarrantLiability	13762000	usd
	DFLI	Noncash Impact Of Cash Exercise Of Liability Classified Warrants NoncashImpactOfCashExerciseOfLiabilityClassifiedWarrants	617000	usd
	DFLI	Cashless Exercise Of Liability Classified Warrants CashlessExerciseOfLiabilityClassifiedWarrants	12629000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_804_eus-gaap--NatureOfOperations_ztJrwEFnyILj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif; text-transform: uppercase"><b>Note 1 - <span id="xdx_82F_zx8uwLTBea0d">NATURE OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dragonfly Energy Holdings Corp. (“New Dragonfly” or the “Company”) sells lithium-ion battery packs for use in a wide variety of applications. The Company sells to Original Equipment Manufacturers (“OEMs”) under the Dragonfly Energy brand name, and sells direct to consumers under the trade name Battleborn Batteries. In addition, the Company develops technology for improved lithium-ion battery manufacturing and assembly methods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 7, 2022, a merger transaction between Chardan NexTech Acquisition 2 Corporation (“CNTQ”), Dragonfly Energy Corp. (“Legacy Dragonfly”), and Bronco Merger Sub, Inc. (“Merger Sub”) was completed pursuant to which Merger Sub was merged with and into Legacy Dragonfly, with Legacy Dragonfly surviving the merger. As a result of the merger, Legacy Dragonfly became a wholly owned subsidiary of New Dragonfly.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although New Dragonfly was the legal acquirer of Legacy Dragonfly in the merger, Legacy Dragonfly was deemed to be the accounting acquirer, and the historical financial statements of Legacy Dragonfly became the basis for the historical financial statements of New Dragonfly upon the closing of the merger. New Dragonfly together with its wholly owned subsidiary, Dragonfly Energy Corp., is referred to hereinafter as the “Company.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore, the historical financial statements of Legacy Dragonfly became the historical financial statements of the Company upon the consummation of the merger. As a result, the financial statements included in this Quarterly Report reflect: (i) the historical operating results of Legacy Dragonfly prior to the merger; (ii) the combined results of CNTQ and Legacy Dragonfly following the close of the merger; (iii) the assets and liabilities of Legacy Dragonfly at their historical cost and (iv) the Legacy Dragonfly’s equity structure for all periods presented, as affected by the recapitalization presentation after completion of the merger.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Cash Cash	13235000	usd
	DFLI	Working Capital WorkingCapital	22000000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7260000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	41907000	usd
	DFLI	Period Within Which Payment Is Due From Customers PeriodWithinWhichPaymentIsDueFromCustomers	30 – 90 days
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	178000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	90000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	49846000	usd
	us-gaap	Depreciation Depreciation	909000	usd
	us-gaap	Depreciation Depreciation	648000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	316000	usd
CY2022Q3	us-gaap	Depreciation Depreciation	259000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_zpgRyH8Im0Nb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_86A_zsjdmFXXpQwb">Use of Estimates</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	217000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	238000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	230000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	434000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15889000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26117000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	53954000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	66042000	usd
	DFLI	Shipping And Handling Costs ShippingAndHandlingCosts	2872000	usd
	DFLI	Shipping And Handling Costs ShippingAndHandlingCosts	4042000	usd
CY2023Q3	DFLI	Shipping And Handling Costs ShippingAndHandlingCosts	913000	usd
CY2022Q3	DFLI	Shipping And Handling Costs ShippingAndHandlingCosts	1508000	usd
CY2023Q3	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	301000	usd
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	328000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zeOe5BdHNtL2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_861_zfmpg5Jz7rY6">Concentrations</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivables from <span id="xdx_90B_ecustom--NumberOfCustomers_pid_dc_uCustomer_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CreditConcentrationRiskMember_zHKtZ8vlQVy2" title="Number of customers">two</span> customers comprised approximately <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CreditConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zV2ykLXDhR92" title="Concentration risk, percentage">38</span>% and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CreditConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_ztZqeMuMOZAc" title="Concentration risk, percentage">15</span>%, respectively, of accounts receivable as of September 30, 2023. Receivables from three customers comprised approximately <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CreditConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zZPPlA8vBakc" title="Concentration risk, percentage">18</span>%, <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CreditConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zxBPcbqcbLv7" title="Concentration risk, percentage">10</span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CreditConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zamhC6fA7Z11" title="Concentration risk, percentage">10</span>%, respectively, of accounts receivable as of December 31, 2022. There are no other significant accounts receivable concentration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales from <span id="xdx_901_ecustom--NumberOfCustomers_pid_dc_uCustomer_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWlfSFLrMHNg">one</span> customer comprised approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zepBB0kSFg27" title="Concentration risk, percentage">19</span>% of revenue for the nine months ended September 30, 2023. <span id="xdx_909_ecustom--NumberOfCustomers_pid_dc_uCustomer_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zQdszJykiOne">One</span> customer accounted for approximately <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zgZaIRPZU8s1" title="Concentration risk, percentage">20</span>% of the Company’s total revenue for the nine months ended September 30, 2022. Sales from <span id="xdx_90F_ecustom--NumberOfCustomers_pid_dc_uCustomer_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zpUj3s2Eo8Fj">one</span> customer comprised approximately <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zbk5AxRxOLN9" title="Concentration risk, percentage">11</span>% of revenue for the three months ended September 30, 2023. <span id="xdx_902_ecustom--NumberOfCustomers_pid_dc_uCustomer_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGV4AEozgCL7">One</span> customer accounted for approximately <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zrfCS7GhT8Ja" title="Concentration risk, percentage">34</span>% of the Company’s total revenue for the three months ended September 30, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payables to <span id="xdx_907_ecustom--NumberOfVendors_pid_dc_uVendor_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zJ7JSecrIpo4" title="Number of vendors">one</span> vendor comprised approximately <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zIoCSfRQ74m6" title="Concentration risk, percentage">68</span>% of accounts payable as of September 30, 2023. Payables to <span id="xdx_90E_ecustom--NumberOfVendors_pid_dc_uVendor_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zyvJrdLKRq5b" title="Number of vendors">one</span> vendor comprised approximately <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zE4y5DsKDvk2" title="Concentration risk, percentage">61</span>% of accounts payables as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the nine months ended September 30, 2023, <span id="xdx_905_ecustom--NumberOfVendors_pid_dc_uVendor_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TotalPurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_ziLjLQ3KZAn9" title="Number of vendors">one</span> vendor accounted for approximately <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TotalPurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zZM9Huoujgll" title="Concentration risk, percentage">16</span>% of the Company’s total purchases. For the nine months ended September 30, 2022, <span id="xdx_90B_ecustom--NumberOfVendors_pid_dc_uVendor_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TotalPurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zgX9jFHezrtd" title="Number of vendors">one</span> vendor accounted for approximately <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TotalPurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zJephuoscM4k" title="Concentration risk, percentage">24</span>% of the Company’s total purchases. For the three months ended September 30, 2023, <span id="xdx_905_ecustom--NumberOfVendors_pid_dc_uVendor_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TotalPurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z6krOwSByOJ2" title="Number of vendors">three</span> vendors accounted for approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TotalPurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zasjXH24THoh" title="Concentration risk, percentage">14</span>%, <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TotalPurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_zIhyBYikIBN7" title="Concentration risk, percentage">11</span>%, and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TotalPurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorThreeMember_zg3EjE4nnLA5" title="Concentration risk, percentage">10</span>%, respectively, of the Company’s total purchases. For the three months ended September 30, 2022, <span id="xdx_90F_ecustom--NumberOfVendors_pid_dc_uVendor_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TotalPurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zbM6NKy0Tnq4" title="Number of vendors">three</span> vendors accounted for approximately <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TotalPurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorOneMember_zQ0LnQSpHeAe" title="Concentration risk, percentage">20</span>%, <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TotalPurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorTwoMember_zejJELcANY97" title="Concentration risk, percentage">10</span>%, and <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--TotalPurchasesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--VendorThreeMember_zansBt2UkoTl" title="Concentration risk, percentage">10</span>%, respectively, of the Company’s total purchases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	36850000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	42586000	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5057000	usd
	us-gaap	Advertising Expense AdvertisingExpense	2020000	usd
	us-gaap	Advertising Expense AdvertisingExpense	1777000	usd
CY2023Q3	us-gaap	Advertising Expense AdvertisingExpense	750000	usd
CY2022Q3	us-gaap	Advertising Expense AdvertisingExpense	515000	usd
CY2023Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	128000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	128000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q1	DFLI	Lessee Operating Lease Monthly Base Rent LesseeOperatingLeaseMonthlyBaseRent	230000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	23000	usd
CY2022Q1	DFLI	Lessee Operating Lease Estimated Monthly Property Taxes LesseeOperatingLeaseEstimatedMonthlyPropertyTaxes	21000	usd
CY2022Q1	DFLI	Lessee Operating Lease Percentage Of Escalation Of Monthly Base Rent LesseeOperatingLeasePercentageOfEscalationOfMonthlyBaseRent	0.03	pure
CY2022Q1	DFLI	Lessee Operating Lease Percentage Of Escalation Of Fix Operating Expense Costs LesseeOperatingLeasePercentageOfEscalationOfFixOperatingExpenseCosts	0.024	pure
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3615000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4513000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1264000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1188000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2565000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3541000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	3829000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4729000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y7M6D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.052	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.052	pure
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	353000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1435000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1435000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	893000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4116000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	287000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	3829000	usd
CY2023Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	55955000	usd
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	18700000	usd
	DFLI	Stock Issued During Period Shares Exercise Of Public Warrants StockIssuedDuringPeriodSharesExerciseOfPublicWarrants	64971	shares
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	389000	usd
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	400000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1177000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1046000	usd
CY2023Q3	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P3Y
CY2022Q3	us-gaap	Lessee Finance Lease Term Of Contract1 LesseeFinanceLeaseTermOfContract1	P5Y
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	112000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	45000	usd
CY2023Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	36000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	10000	usd
CY2023Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	75000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	38000	usd
CY2023Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	111000	usd
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	48000	usd
CY2023Q3	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P4Y2M12D
CY2023Q3	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.052	pure
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.052	pure
CY2023Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	18700000	usd
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	100000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	76000	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.50
	DFLI	Stock Issued During Period Value Exercise Of Public Warrants StockIssuedDuringPeriodValueExerciseOfPublicWarrants	747000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	10000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	41000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	41000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	24000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	4000	usd
CY2023Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	120000	usd
CY2023Q3	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	9000	usd
CY2023Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	111000	usd
CY2023Q3	DFLI	Business Acquisition Equity Interest Issued Or Issuable Additional Number Of Shares BusinessAcquisitionEquityInterestIssuedOrIssuableAdditionalNumberOfShares	40000000	shares
	DFLI	Audited Revenue AuditedRevenue	250000000	usd
	DFLI	Audited Operating Income AuditedOperatingIncome	35000000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	5275	usd
	DFLI	Liquidity Description LiquidityDescription	The Company shall not permit their Liquidity (determined on a consolidated basis) to be less than $10,000 as of the last day of each fiscal month (commencing with month ending December 31, 2022).
	DFLI	Fixed Charge Coverage Ratio Description FixedChargeCoverageRatioDescription	The Fixed Charge Coverage Ratio is the ratio of consolidated EBITDA (less capital expenditures and certain other adjustments) to consolidated fixed charges, as defined in the agreement. If Liquidity is less than $15,000 as of the last day of any fiscal quarter (commencing with the quarter ended December 31, 2022), then the Company shall not permit the Fixed Charge Coverage Ratio for the trailing four quarterly periods ending on the last day of any such quarter to be less than 1.15 to 1.00.
	DFLI	Capital Expenditures Description CapitalExpendituresDescription	If consolidated EBITDA for the trailing twelve-month period ending on the most recently completed fiscal quarter is less than $15,000, then the level of capital expenditures is limited.
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	938000	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	3750000	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	74931000	usd
CY2023Q3	DFLI	Long Term Debt Maturities Repayments Of Principal LongTermDebtMaturitiesRepaymentsOfPrincipal	79619000	usd
CY2023Q3	DFLI	Estimated Interest Paidinkind EstimatedInterestPaidinkind	-4964000	usd
CY2023Q3	us-gaap	Long Term Debt LongTermDebt	74655000	usd
	DFLI	Class Of Warrant Or Right Exercisable To Purchase Description ClassOfWarrantOrRightExercisableToPurchaseDescription	the Company issued (i) the penny warrants to the Term Loan Lenders exercisable to purchase an aggregate of 2,593,056 shares of Common Stock (the “Penny Warrants”) and (ii) the $10 warrants to issue warrants to the Term Loan Lenders exercisable to purchase an aggregate of 1,600,000 shares of Common Stock at $10 per share (the “$10 Warrants” and, together with the Penny Warrants, the “Term Loan Warrants”). The $10 Warrants were exercised on a cashless basis on October 10, 2022, with the Company issuing 457,142 shares of Common Stock in connection with such exercise.
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58880712	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58880712	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43272728	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43272728	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3274940	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3665099	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58880712	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38576658	shares
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	23219622	shares
CY2023Q3	DFLI	Earnout Shares EarnoutShares	40000000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4470153	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	639395	shares
CY2023Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	129845427	shares
CY2022Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	42881152	shares
	us-gaap	Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable	2028-06-20
	DFLI	Proceed From Issuance Of Common Stock ProceedFromIssuanceOfCommonStock	22810000	usd
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	2074000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1169000	usd
CY2023Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	13762000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6387000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1155000	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	946000	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	436000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3690955	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.98
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.38
	DFLI	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P8Y6M7D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6550000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	602275	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.08
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.81
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.29
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	2.07
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	580760	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.44
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.89
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3665099	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.40
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M19D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5220000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3642958	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.02
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.21
	DFLI	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P7Y10M24D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	35989000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	143607	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.50
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.82
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	303433	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.50
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	1.89
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	208192	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.72
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.96
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3274940	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.14
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.28
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y18D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2235282	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	1.68
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y25D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1403000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3274940	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.14
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y18D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1466000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10023000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3689000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16831000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7456000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58736013	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58736013	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38129422	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38129422	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50166320	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50166320	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37098990	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37098990	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	26711562	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3665099	shares
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1700000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
dfli-20230930_def.xml	Edgar Link	unprocessable
0001493152-23-041072-index-headers.html	Edgar Link	pending
0001493152-23-041072-index.html	Edgar Link	pending
0001493152-23-041072.txt	Edgar Link	pending
0001493152-23-041072-xbrl.zip	Edgar Link	pending
dfli-20230930.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
dfli-20230930_cal.xml	Edgar Link	unprocessable
dfli-20230930_pre.xml	Edgar Link	unprocessable
dfli-20230930_lab.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DFLI
Dragonfly Energy Holdings Corp. Stock $dfli

2023 Q4 Form 10-Q Financial Statement

#000149315223041072 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DFLI Dragonfly Energy Holdings Corp. Stock $dfli

2023 Q4 Form 10-Q Financial Statement

#000149315223041072 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DFLI
Dragonfly Energy Holdings Corp. Stock $dfli